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Abstract We examined the prevalence of HIV disclosure
to sexual partners by HIV-positive drug injectors (IDUs) in
St. Petersburg, Russia and compared the magnitude and
direction of associations of condom use with awareness of
one’s HIV infection and disclosure to partners. Among 157
HIV-infected participants, awareness of infection at time of
last intercourse was associated with condom use with
partners perceived to be HIV-negative (aOR 6.68, 95% CI
1.60–27.88). Among the 70 participants aware of their
infection prior to enrolment, disclosure to potentially
uninfected sexual partners was independently and nega-
tively associated with condom use (aOR 0.13, 95% CI
0.02–0.66). Disclosure was independently associated with
having injected C9 years (aOR 6.04, 95% CI 1.53–23.77)
and partnership with another IDU (aOR 3.61, 95% CI
1.44–9.06) or HIV-seropositive (aOR 45.12, 95% CI
2.79–730.46). Scaling up HIV testing services and inter-
ventions that increase the likelihood of individuals
receiving their test results is recommended.
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Introduction
Russia faces one of the most rapidly expanding AIDS
epidemics [1, 2], with more than 470,000 registered HIV
cases at the end of 2008 and the estimated number of
infections exceeding one million [3, 4]. Thus far, the
overwhelming majority of those infected are injection drug
users (IDUs) [1, 2, 5–8]. Estimates of HIV seroprevalence
among St. Petersburg IDUs indicate a rise from 2–4% in
1998 to 11–18% in 2000 to 30% in 2002 to 49% in 2008
[9–14]. There is also evidence that HIV is spreading to the
general population via heterosexual contact [7, 15–17].
In the West and particularly in the US, recent HIV
prevention efforts have focused on promoting HIV coun-
seling and testing with disclosure of HIV serostatus to
prospective sexual partners [18, 19]. Estimates of the
proportions of HIV-infected heterosexuals in the West who
disclose to partners range from 60 to 80% [20–22]. By
contrast, the issue of disclosure and its potential public
health impact is largely unexplored in Russia. Only limited
anonymous HIV testing is available in Russia, and lack of
access to treatment as well as the pervasive stigma asso-
ciated with HIV disease [23, 24] often dissuade people
from being tested. Although many Russians have been
tested for HIV at least once in their lives, the testing most
commonly occurs as a result of incarceration or an in-
patient medical visit. Only approximately one in ﬁve IDUs
who self-identify as HIV-negative had been tested within
the previous year [25]. Since HIV testing is not as prevalent
as in the West, the relationship between awareness of one’s
HIV status, disclosure, and condom use is poorly under-
stood. The current study is the ﬁrst to examine these issues
within a sample of IDUs in St. Petersburg, Russia.
In several US studies, disclosure appears to be inﬂu-
enced by contextual, temporal, and situational factors [26,
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mary or anonymous partners [22, 26–33]. Studies suggest
that the spread of HIV may be fueled by a relatively small
number of infected individuals who engage in multiple
high-risk behaviors (e.g., multiple partners, unprotected
sex) without disclosure [27, 34–36]. Partner characteristics
also inﬂuence disclosure behavior such that disclosure was
less likely to occur with younger partners [37] or with those
whose serostatus is understood to be negative or to be
unknown [28, 38–40]. Additionally, timing of disclosure
(i.e., prior or subsequent to unprotected sex) is not clearly
identiﬁed [27], and therefore, sex partners may underesti-
mate their HIV risk [38, 41, 42]. People need time to adjust
to their diagnosis—typically 2–3 years—after which time
disclosure is more likely to occur [39, 43–45].
The few studies assessing HIV testing awareness in
Russia or other countries of the former Soviet Union sug-
gest that fewer than 40% of Russian participants were
aware of their partner’s HIV status at time of sex [25, 46].
Pervasive stigma surrounding HIV in Russia [23, 24] may
dissuade people from disclosing [47]. We are unaware of
any scientiﬁc publications that speciﬁcally examine HIV
disclosure behavior among Russian IDUs, although there is
some evidence from Western Europe that IDUs’ awareness
of their HIV infection was associated with increased con-
dom use [48]. Since the epidemic is currently concentrated
among IDUs, we begin such explorations by seeking to
identify individual and interpersonal factors that inﬂuence
disclosure and condom use behaviors in this population.
Speciﬁcally, we used data on recent sexual partnerships
from HIV-infected IDUs, only some of whom had been
aware of their infection at time of last intercourse to
address four questions: (1) Among HIV-infected IDUs, is
knowledge of their infection associated with increased
condom use? (2) What individual, partner, and partnership
characteristics are associated with disclosure by HIV-
positive IDUs? (3) Is disclosure by HIV-positive IDUs
associated with condom use? and (4) Is disclosure of
positive status or awareness of positive status more
strongly associated with condom use? This constitutes a
ﬁrst step in determining whether and the extent to which
HIV disclosure should be emphasized in future prevention
interventions for Russian IDUs.
Methods
As part of a larger multi-site, cross-sectional study, ‘‘Sex-
ual Acquisition and Transmission of HIV - Cooperative
Agreement Program’’ (SATH-CAP), data were collected in
St. Petersburg from September 2005 to December 2008.
SATH-CAP seeks to identify the structural, social, and
individual factors associated with HIV risk behavior among
high-risk populations, one of which is users of heroin,
cocaine, or amphetamine-type stimulants, and the sex
partners of these participants. Sampling and recruitment
procedures, data collection instruments, and other study
methods have been reported in detail elsewhere [25, 49];
speciﬁcs relevant to this study are described below.
Participants
Participants were recruited using a modiﬁed version of
respondent-driven sampling (RDS) [49–51]. Previous
analysis found less than 5% overlap between drug users
and men who have sex with men (MSM) and greater than
95% prevalence of injection among the drug users [10, 25].
The present analysis is restricted to SATH-CAP partici-
pants who (1) were 18 years or older, (2) reported injecting
illicit drugs at least once in their life, (3) tested positive for
HIV infection as part of the SATH-CAP serological test-
ing, and (4) supplied information about their sex partners
within the past 6 months (Fig. 1). Participants were pro-
vided incentives equivalent to US$10 for their participation
and US$5 for each person they successfully referred to the
study. All study and consent procedures and study
Ever injected drugs? 
SATH-CAP sample 
(n = 1,023) 
NO (n = 332; 32%) YES (n = 691; 68%)
HIV positive test? 
YES (n = 301; 44%)
NO (n = 391; 56%)
Partner data? 
NO (n = 30; 15%)
YES (n = 157; 76%)
Previously diagnosed HIV-positive? 
YES (n = 70; 45%)
NO (n = 87; 55%)
Had sex in past 6 months? 
NO (n = 38; 13%)
YES (n = 217; 72%)
MSM?  YES (n = 10; 5%)
NO (n = 207; 95%)
No sex data provided (n = 46; 15%)
Partner is also participant (n = 20; 10%)
Fig. 1 Derivation from the SATH-CAP cohort of the subsample
used in the current analyses. We limited the analyses to those
participants who reported ever having injected drugs and who tested
positive for HIV infection at enrolment (n = 300). We ﬁrst examined
the association between prior knowledge of HIV status and condom
use at last intercourse in each of their sexual partnerships.
Subsequently, among participants who were aware of their HIV
infection prior to enrolment, we examined the association between
disclosure of HIV status to and condom use with their reported sex
partners
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123measures were approved by institutional review boards at
The Biomedical Center, Yale University, and RAND
Corporation.
Data Collection, Measures, and Laboratory Procedures
Participants completed a structured, computer-assisted,
self-administered interview and, following pre-test HIV
counseling, had blood drawn for serological testing. Data
used in the present analyses included demographic, medi-
cal history, drug and sex behaviors, sex partner informa-
tion, and HIV serology. Demographic variables included
sex, age, marital status, living situation, educational level,
current employment status, legal income (past 30 days),
and history of incarceration. Medical history items inclu-
ded HIV testing history and whether participants had
received their most recent test results. Participants report-
ing HIV infection were asked the month and year of their
diagnosis. We deﬁne ‘‘HIV-seropositive’’ as seropositive
test results based on the testing performed as part of this
study and ‘‘previously aware of diagnosis’’ as participants
who reported having been informed that they were HIV-
positive prior to enrolling in this study. Drug use data
included duration of injection drug use (median-split at
9 years), number of injections in past 30 days (median-
split at 22), and unsafe injections in past 30 days (yes/no;
deﬁned as sharing needles without using bleach, using a
single syringe to mix or divide drugs, or sharing cookers,
cotton, or water). Sexual behavior data included number of
sex partners in the prior 6 months, number of new partners
in the past 6 months, partner-speciﬁc information (i.e., for
main partner, up to three most recent non-main partners,
and if applicable, a partner with whom they also shared
drugs), and condom use at last sexual intercourse with up to
ﬁve partners in the previous 6 months. Partner-speciﬁc data
included each partner’s age and gender, partnership type
(main vs. casual/friend vs. stranger/sex trade), disclosure of
HIV status to partner, and perceived injection drug use
history of partner. Perceived HIV status was ascertained by
asking about each partner ‘‘What is [the partner’s] HIV
status?’’ and were given as potential responses ‘‘I don’t
know or am not sure’’, ‘‘I am sure he/she is HIV negative’’
and ‘‘I am sure he/she is HIV-positive’’. Participants who
responded that a partner was positive were then asked ‘‘Do
you know [the partner’s] HIV status because he/she told
you him/herself?’’ Participants were also asked for each
partner ‘‘Does [the partner] know your HIV status?’’ Those
answering in the afﬁrmative were then asked ‘‘Does [the
partner] know your HIV status because you told him/her
yourself?’’ We included all reported partnerships in these
analyses except those in the previously aware of diagnosis
group for whom the date of last intercourse occurred before
they became aware of their HIV diagnosis.
Analytical Methods
Standard descriptive statistics were used to describe the
sample. Continuous variables were dichotomized in order to
adapt those with non-normal distributions to parametric
tests and to preserve statistical power. Using Chi-square and
Wilcoxon rank-sum tests, we compared the characteristics
of seropositives who were aware of their HIV infection with
those who were not, examined whether the demographic
characteristics of participants who provided information on
sexual partnerships differed from those who did not, and
examined whether partner characteristics were associated
with the participant’s perception of their partners’ serosta-
tus. We employed population-averaged panel-data models
to account for single participants’ ability to report on more
than one partner. This was accomplished using generalized
estimating equations (GEE), under the command—gee—in
Stata 10 [52]. We used the same technique to assess among
participants who were aware of their infection, whether any
participant, partner, or partnership characteristic was asso-
ciated with disclosure within the partnership.
Among partnerships reported by HIV-infected partici-
pants, we assessed bivariate associations between the par-
ticipant’s awareness of being infected with HIV at the time
of their last sexual encounter and condom use at that time.
We assessed these associations within all reported part-
nerships and within a subset of partnerships with partners
either perceived to be uninfected or of unknown serostatus.
To estimate associations between awareness of infection
and condom use, unconfounded by other available indi-
vidual, partner, and partnership characteristics, we also
assessed associations between condom use and partici-
pant’s age, duration of injection drug use, history of
incarceration, partnership type, and participant’s under-
standing of whether partners also injected drugs and per-
ceived serostatus of partners. In each case, covariates that
were associated in bivariate analyses at P\0.20 were
entered into an initial multivariate model; backward
selection eliminated covariates that did not remain signif-
icant at P\0.05 or did not change other coefﬁcients by
[10%. This was done for all partnerships and the three
aforementioned subsets.
We then limited analysis to participants who were aware
of their HIV infection prior to study enrolment. Among
partnerships reported by these participants, we assessed
bivariate associations between participants’ disclosure of
positive serostatus and condom use, and produced multi-
variate models in the manner described above for all
reported partnerships and the three aforementioned subsets.
To account for potential confounders in any association
between prior awareness of HIV infection and condom use,
we identiﬁed associations between prior diagnosis of HIV
infection and participant characteristics using Chi-square
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ables we used the Wilcoxon rank-sum test. For condom
use, we calculated unadjusted and adjusted correlations
between dependent and independent variables. In each
case, covariates that were associated in bivariate analyses
at P\0.20 were entered into an initial multivariate model;
backward selection eliminated covariates that did not
remain signiﬁcant at P\0.05 or did not change other
coefﬁcients by[10%.
Participants could refer their sex partners to the study,
raising the possibility of double-reporting of sex partner-
ships between two participants, once by the recruiter and
once by the recruit. To account for potential correlation we
nested responses by the participant who had referred the
partner to the study. Therefore, partnerships reported with
participants’ recruiters were excluded from analysis if both
participant and recruiter were present in the subset of
observations analyzed.
Because participants were recruited using RDS, use of
weighting procedures was considered to adjust the sample
for recruitment probabilities to obtain estimates that would
reﬂect the underlying population from which sampling was
conducted. However, in prior analyses of these data, pro-
portions of demographic and serologic characteristics did
not differ substantially between weighted and unweighted
distributions. Therefore, we used unweighted estimates for
these analyses [25].
Results
Characteristics of the Study Sample
Of 691 participants who reported a history of drug injec-
tion, 301 (44%) tested HIV-seropositive at the time of
enrolment. Among these seropositive participants, 38
reported having no sex partners, 46 participants provided
no data on the number of sex partners they had in the prior
6 months (therefore not asked partner-speciﬁc items), and
30 declined to provide partnership data. We also excluded
from analysis ten males who reported sex with male part-
ners only and 20 participants who reported sex partnership
only with their recruiter. Thus, we restricted analyses to the
157 heterosexual, HIV-seropositive participants who pro-
vided data on 231 non-overlapping partnerships (Fig. 1).
We found no signiﬁcant demographic differences between
participants who provided data partnership data and those
who did not.
Nearly two-thirds of the resulting sample were male
(65%). The median age was 28 years (25%, 75% = 24,
32 years), with approximately twice as many single par-
ticipants as married/partnered participants. Most partici-
pants (69%) lived with either their families or friends. Over
half (56%) had at least some post-secondary education.
Few (37%) were currently employed; median income from
legal sources was 1,625 rubles (US$50) in the last month
(25%, 75% = 0, 7,000 rubles; data not shown). Fewer than
half the participants (42%) reported ever having been
incarcerated. The median duration of injection drug use
was 9.2 years (25%, 75% = 6, 11; data not shown), and
nearly all (92%) reported injecting within the prior
30 days. The median number of injections in the prior
30 days was 23 (25%, 75% = 10, 30; data not shown); the
majority of participants (79%) reported injecting unsafely
(e.g., sharing syringe, cooker, cotton, and/or water) at least
once in the prior 30 days. In the previous 6 months, 61%
reported having sex with a new partner, and 40% reported
having more than one partner (Table 1).
Most participants (80%) reported having been tested for
HIV at least once (Table 1), and of those tested, most
(82%) reported having received their test results (data not
shown). Less than half (45%) the sample reported having
been aware of their HIV infection prior to enrolment. Of
these, 73% had received their positive test results more
than 2 years ago (data not shown); no date of diagnosis was
available for 3 of the 70 participants who were previously
aware of their HIV infection. No participant characteristic
was signiﬁcantly associated with prior diagnosis of HIV
infection save marital status (v
2 = 6.64, P = 0.042;
Table 1).
Characteristics of Participants’ Reported Sex Partners
Participants reported approximately one in ﬁve partners
(19%) to be HIV-seropositive, with most partners (80%)
communicating this information directly to the participant
(data not shown). Of the partners perceived to be sero-
negative (31%), participants reported asking most (71%)
whether they had been tested for HIV (data not shown). Of
the partners whose serostatus was ‘‘unknown’’ to the par-
ticipant (50%), fewer than a third (29%) had been asked by
the participant whether they had been tested for HIV (data
not shown). Participants were no more likely to report
knowing the HIV status of their primary sex partners than
of their other partners. Participants were more likely to
perceive IDU partners as HIV-positive than as seronegative
or of unknown serostatus (P\0.001; data not shown). No
other partner characteristic (e.g., partner’s gender, partner’s
age, partnership type) was associated with perception of
partner’s serostatus.
Association Between Previous Awareness of HIV
Diagnosis and Condom Use at Last Intercourse
Participants reported using condoms at last intercourse in
115 (50%) of 231 partnerships (Table 2). Awareness of
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123one’s HIV infection was not associated with condom use in
a model that included all partners regardless of partici-
pants’ perception of partner serostatus. Instead, participants
were less likely to use condoms with their primary partners
(aOR 0.60, 95% CI 0.38–0.96; P = 0.034) and with IDU
partners (aOR 0.39, 95% CI 0.23–0.66; P\0.001). In a
Table 1 Characteristics
of HIV seropositive drug
injectors, by previous diagnosis
of HIV infection, St. Petersburg,
Russia (2005–2008) (n = 157
unless otherwise noted)
a Median (25th percentile, 75th
percentile)
b Excludes participants who did
not report having injected in the
past 30 days
c Z-score for Wilcoxon rank-
sum test
d Fisher’s exact Chi-square
Characteristic No. (%)
diagnosed
No. (%)
undiagnosed
Total v
2 P
Total 70 (45) 87 (55) 157 (100)
Gender
Male 44 (63) 58 (67) 102 (65) 0.247 0.619
Female 26 (37) 29 (33) 55 (35)
Age
a 28 (25, 32) 28 (24, 32) 28 (24, 32) -0.540
c 0.590
Marital status
Married or partnered 22 (31) 37 (43) 58 (38) 6.635 0.042
Single, divorced, widowed or separated 48 (69) 50 (57) 98 (62)
Living situation
Alone or with partner 24 (34) 22 (25) 46 (29) 0.323
d 0.315
With family or friends 44 (63) 64 (74) 108 (69)
Shelter or SRO 2 (3) 1 (1) 3 (2)
Postsecondary education
Yes 39 (56) 49 (56) 88 (56) 0.006 0.939
No 31 (44) 38 (44) 69 (44)
Full/part-time employment
Yes 26 (37) 32 (37) 58 (37) 0.002 0.963
No 44 (63) 55 (65) 99 (63)
Any legal income (past 30 days)
Yes 44 (66) 48 (65) 90 (92) 0.009 0.926
No 22 (34) 26 (35) 48 (35)
Ever in jail or prison
Yes 34 (49) 32 (37) 66 (42) 2.213 0.137
No 36 (51) 55 (63) 91 (58)
Ever tested for HIV
Yes 70 (100) 55 (63) 125 (80) 32.338
d \0.001
No 0 (0) 32 (37) 32 (20)
Injecting for past 9 years or longer
Yes 40 (57) 39 (45) 79 (50) 2.353 0.125
No 30 (43) 48 (55) 78 (50)
Injected last 30 days
Yes 64 (94) 77 (91) 141 (92) 0.550
d 0.420
No 4 (6) 8 (9) 12 (8)
Injections/month[22
b
Yes 29 (45) 42 (55) 71 (50) 1.192 0.275
No 35 (55) 35 (45) 70 (50)
Unsafe injection 30 days
b
Yes 52 (81) 60 (78) 112 (79) 0.237 0.626
No 12 (19) 17 (22) 29 (21)
New sex partner, 6 months
Yes 43 (61) 52 (60) 95 (61) 0.045 0.833
No 27 (39) 35 (40) 62 (39)
More than one sex partner, 6 months
Yes 27 (39) 36 (41) 63 (40) 0.127 0.721
No 43 (61) 51 (59) 94 (60)
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123Table 2 Correlates of condom use at last sexual intercourse among drug injectors in St. Petersburg, Russia
Total Used condom
No. (%)
uOR 95% CI P-value aOR 95% CI P-value
With any partner nparticipants = 157
Total partnerships 231 115 (50) – – – –
Awareness of infection in positive injector
Yes 106 52 (49) 1.19 0.64–2.20 0.587
No 125 63 (50) Ref
Gender
Male 152 81 (53) 1.52 0.80–2.90 0.207
Female 79 34 (43) Ref
Age 28 plus
Yes 121 64 (53) 1.41 0.76–2.62 0.270
No 110 51 (46) Ref
Inject 9 years
Yes 115 63 (55) 1.54 0.83–2.85 0.168
No 116 52 (45) Ref
IDU’s perception of partner’s serostatus
Positive 44 18 (41) Ref
Negative 71 40 (56) 1.79 0.87–3.71 0.114
Unknown 115 57 (50) 1.28 0.66–2.51 0.466
Partner type
Main 104 50 (48) 0.67 0.43–1.05 0.078 0.60 0.38–0.96 0.034
Other 100 61 (61) Ref
Partner injects drugs
Yes 125 48 (38) 0.36 0.23–0.58 \0.001 0.39 0.23–0.66 \0.001
No 95 50 (63) Ref Ref
With partners perceived to be seronegative nparticipants = 50
Total partnerships 71 40 (56) – –
Awareness of infection in positive injector
Yes 27 19 (70) 3.76 1.11–12.66 0.033 6.68 1.60–27.88 0.009
No 44 20 (48) Ref Ref
Gender
Male 50 30 (60) 1.75 0.55–5.52 0.344
Female 21 10 (48) Ref
Age 28 plus
Yes 33 20 (61) 1.25 0.44–3.58 0.677
No 38 20 (53) Ref
Inject 9 years
Yes 34 21 (62) 1.59 0.55–4.58 0.391
No 37 19 (51) Ref
Partner type
Main 38 19 (50) 0.52 0.22–1.20 0.125
Other 29 20 (69) Ref
Partner injects
Yes 23 10 (43) 0.42 0.17–1.06 0.060 0.29 0.11–0.74 0.009
No 48 30 (63) Ref Ref
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stood to be seronegative and adjusted for the strong neg-
ative correlation of condom use with partner’s injection
drug use, participants’ awareness of their HIV infection
was associated with condom use (aOR 6.68, 95% CI
1.60–27.88; P = 0.009). In a model of partnerships with
sex partners of unknown serostatus, participants who had
been aware of their HIV infection at the time of sexual
intercourse were no more likely to have used condoms than
those who had been unaware. Similar to the ﬁndings for all
partners, participants were less likely to use condoms with
partners assumed to be an IDU (aOR 0.32, 95% CI
0.17–0.62; P = 0.001).
Prevalence and Correlates of Disclosure of Positive
Status
The 70 participants who had been aware of their HIV
infection prior to enrolment provided data on 106 part-
nerships. They reported disclosing their HIV status in 73%
of these partnerships (data not shown). Participant disclo-
sure was associated with having injected longer than
9 years (aOR 6.04, 95% CI 1.53, 23.77; P = 0.010) and
with partners whom they perceived to be seropositive (aOR
45.12; 95% CI 2.79, 730.46; P = 0.007) or IDUs (aOR
3.61; 95% CI 1.44, 9.06; P = 0.006) (data not shown). No
other participant characteristic (e.g., demographic, time
since diagnosis, duration of drug use, incarceration history)
or partnership characteristic (e.g., partnership type, part-
ner’s age) was associated with disclosure behavior.
Association Between HIV Disclosure and Condom Use
Among Participants Who Had Been Previously Aware
of Their HIV Infection
Participants who were previously aware of their HIV infec-
tion used condoms at last intercourse in 52 (49%) of 106
partnerships (Table 3). Condoms were used in a minority of
encounters with partners perceived to be positive (36%);
their use was signiﬁcantly more common with partners
perceived to be negative (70%) but only slightly more likely
with partners whose serostatus was perceived as unknown
(48%). Disclosure was not independently associated with
condomuse.Instead,condomusedifferedonlybyperceived
negative serostatus of partner when comparing them to
partners perceived to be seropositive (aOR 3.85, 95% CI
1.45–10.21, P = 0.007; Table 3) or to all other partners
(aOR 2.95, 95% CI 1.29–6.73 P\0.05; data not shown).
Perception of partner status was independently associated
with condom use and was not confounded by any other
Table 2 continued
Total Used condom
No. (%)
uOR 95% CI P-value aOR 95% CI P-value
With partners of unknown status n participants =8 1
Total partnerships 115 57 (50) – –
Awareness of infection in positive injector
Yes 40 19 (48) 1.01 0.41–2.46 0.989
No 75 38 (51) Ref
Gender
Male 77 40 (52) 1.67 0.66–4.33 0.278
Female 38 17 (45) Ref
Age 28 plus
Yes 61 34 (55) 1.91 0.79–4.58 0.150
No 54 23 (43) Ref
Inject 9 years
Yes 58 33 (57) 1.86 0.78–4.43 0.162
No 57 24 (42) Ref
Partner type
Main 46 23 (50) 0.76 0.38–1.49 0.419
Other 56 32 (57) Ref
Partner injects
Yes 65 25 (38) 0.32 0.17–0.62 0.001 0.32 0.17–0.62 0.001
No 39 25 (64) Ref Ref
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Total Used condom
No. (%)
uOR 95% CI P-value aOR 95% CI P-value
With any partner nparticipants = 70
Total partnerships 106 52 (49) – –
Disclosure of status by positive injector
Yes 77 34 (44) 0.46 0.70–0.98 0.028
No 29 18 (62) Ref
Gender
Male 67 38 (57) 2.09 0.81–5.41 0.129
Female 39 14 (36) Ref
Age 28?
Yes 69 32 (53) 1.91 0.75–4.85 0.176
No 47 20 (43) Ref
Known ? 2 years
Yes 77 39 (52) 1.59 0.55–4.58 0.392
No 26 10 (38) Ref
Ever in jail or prison
Yes 50 21 (42) 0.58 0.23–1.45 0.241
No 56 31 (55) Ref
Inject 9 years?
Yes 95 49 (52) 1.98 0.78–5.03 0.150
No 11 3 (27) Ref
IDU’s perception of partner’s serostatus
Positive 39 14 (36) Ref Ref
Negative 27 19 (70) 3.85 1.45–10.21 0.007 3.85 1.45–10.21 0.007
Unknown 40 19 (48) 1.60 0.68–3.77 0.282 1.60 0.68–3.77 0.282
Partner type
Main 41 18 (44) 0.58 0.30–1.11 0.098
Other 51 33 (65) Ref
Partner injects
Yes 67 29 (43) 0.49 0.25–0.96 0.038
No 33 19 (58) Ref
With partners perceived to be seronegative or perceived unknown nparticipants = 43
Total partnerships 67 19 (70) – –
Disclosure of status by positive injector
Yes 40 20 (50) 0.46 0.0.19–1.12 0.089 0.13 0.02–0.66 0.014
No 27 18 (67) Ref Ref
Gender
Male 46 30 (65) 3.10 0.85–11.28 0.086 23.61 1.59–349.97 0.022
Female 21 8 (38) Ref Ref
Age 28?
Yes 35 24 (69) 2.52 0.79–8.03 0.040
No 32 14 (44) Ref
Known ? 2 years
Yes 49 29 (49) 2.41 0.60–9.71 0.217
No 15 6 (40) Ref
Ever in jail or prison
Yes 31 14 (45) 0.44 0.14–1.42 0.173 0.02 0.0–0.30 0.005
No 36 24 (67) Ref
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123variable. In a model limited to partners perceived to be
susceptible to HIV infection (i.e., perceived to be seroneg-
ative or of unknown serostatus), disclosure was indepen-
dently and negatively associated with condom use (aOR
0.13, 95% CI 0.02–0.66; P = 0.014). In the same model
there was a positive and independent association between
condomuseandmalegenderofparticipant(aOR23.61,95%
CI 1.59–349.97, P = 0.022). In addition, condoms were
more likely to be used with partner of perceived negative
serostatus compared to partner of unknown serostatus (aOR
8.65, 95% CI 1.67–44.65, P = 0.010).
Potential for HIV Transmission in Unprotected
Serodiscordant Partnerships
We calculated the number of partnerships with the poten-
tial for HIV transmission, that is, unprotected sex part-
nerships between HIV-seropositive participants and
partners perceived to be either seronegative or of unknown
serostatus (n = 89). The vast majority of these were
unprotected vaginal sex, with only four encounters noting
the occurrence of unprotected anal sex. Among these,
partnerships in which participants had been unaware of
26%
3%
7%
6%
17%
42%
Aware, Partner HIV Negative, Did Not Disclose
Aware, Partner HIV Unknown, Did Not Disclose
Aware, Partner HIV Negative, Disclosed
Aware, Partner HIV Unknown, Disclosed
Unaware, Partner HIV Unknown
Unaware, Partner HIV Negative
Fig. 2 Unprotected sex between HIV-seropositive participants and
partners who were vulnerable to HIV infection (n = 89). Of the 89
unprotected sexual encounters between HIV-seropositive participants
and partners perceived to be either seronegative or of unknown sero-
status, 23 (26%) occurred between participants unaware of their HIV
infection and seronegative partners, 37 (42%) between participants
unaware of their infection and a partner of unknown serostatus, 5
(6%) between participants who knew of their infection and had
disclosed to the seronegative partner, 3 (3%) between participants
who knew of their infection and seronegative partners but without
disclosure, 6 (7%) between participants who knew of their infection
and partners of unknown status but without disclosure, and 15 (17%)
between participants who knew of their infection and had disclosed to
the partner of unknown serostatus. Hence, there were only approx-
imately 3% of unprotected sexual encounters in which disclosure of
serostatus may have inﬂuenced the decision to use a condom. (Color
ﬁgure online)
Table 3 continued
Total Used condom
No. (%)
uOR 95% CI P-value aOR 95% CI P-value
Inject 9 years?
Yes 37 25 (68) 2.19 0.69–6.95 0.182 25.95 2.65–253.81 0.005
No 30 13 (43) Ref
IDU’s perception of partner’s serostatus
Negative 27 19 (70) 2.61 1.00–6.77 0.049 8.65 1.67–44.65 0.010
Unknown 40 19 (48) Ref
Partner type
Main 25 12 (48) 0.61 0.26–1.42 0.249
Other 37 25 (68) Ref
Partner injects
Yes 34 18 (53) 0.60 0.26–1.41 0.244
No 27 16 (59) Ref
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123their HIV infection and understood their partner to be HIV-
negative comprised 26% (n = 23), and partnerships in
which participants had been aware of their infection but
had not disclosed to their seronegative partners comprised
3% (n = 3; Fig. 2).
Discussion
The study results indicate that mere awareness of one’s own
HIV infection is not associated with condom use. Rather,
among IDUs who were aware of their HIV infection, part-
ner’s perceived serostatus was the strongest predictor of
condom use at last intercourse. Compared to partnerships
with partners perceived to be positive or of unknown se-
rostatus, partnerships between IDUs who were aware of
their infection and partners perceived to be seronegative
were characterized by a relative lack of disclosure but more
condom use. Consistent with other studies [40, 53, 54], we
found that disclosure was not associated with increased
condom use. Instead, disclosure to potentially negative
partners was associated with less condom use.
Among participants who were aware of their HIV
infection at time of last intercourse, disclosure was inde-
pendently associated with (1) the perception that their sex
partner was also HIV-positive, (2) the perception that their
partner was also an IDU, and (3) the participant having
injected for at least 9 years. The ﬁrst ﬁnding is consistent
with other studies’ ﬁndings that disclosure was less likely
when partners’ serostatus was either seronegative or
unknown [28, 38–40]. Disclosure to partners who were
perceived to be fellow injectors may be related to the ﬁrst
ﬁnding and reﬂects the harsh reality of HIV in Russia: that
anyone who injects drugs is likely to become infected. The
fact that no other personal or partner characteristics or
partnership type were associated with disclosure contrasts
with studies of disclosure practices among US populations
[22, 26–33, 37, 43, 44, 55]. Further research is warranted to
conﬁrm or refute our ﬁndings.
Among HIV-positive IDUs who were aware of their
infection, it appears that the perception of partners as
uninfected, more than the act of disclosure, was associated
with condom use. Potential exposure of perceived negative
partners was much more common among participants who
had been unaware of their HIV infection at the time of last
sexual contact. We applied the adjusted odds ratio between
prior diagnosis of HIV infection and condom use with
partners perceived to be negative given in Table 2 (aOR:
6.68, CI: 1.60–27.88) and the proportion of partnerships in
which an undiagnosed participant with HIV infection had
exposed potentially uninfected partners (0.26, binomial CI:
0.17–0.36) to a standard formula for population attributable
risk percent (PAR%).
PAR% ¼ PexposedðRR   1Þ=½1 þ PexposedðRR   1Þ 
This suggests that if half of the undiagnosed HIV-infected
IDUs from the sampling frame were to learn of their HIV
infection, the number of potentially uninfected partners
being exposed by infected injectors would be reduced by
60% (CI 9–90%). Conversely, disclosure of HIV infection
to potentially uninfected partners was associated with a
somewhat lesser likelihood of using condoms. It is of
interest that males who were aware of their HIV infection
were signiﬁcantly more likely than females to report hav-
ing used a condom at time of last intercourse. This may be
due to the fact that, compared to females, males can more
easily opt to use a condom with minimal need for condom
negotiation and no need for disclosure.
Limitations of the study included the inherent potential
biases associated with self-reported data such as recall bias
and social desirability. Due to the relatively small sample
size, there was insufﬁcient power to detect effect modiﬁ-
cation; under these conditions, stratiﬁcation was considered
to be the appropriate analytic approach. The cross-sectional
nature of this study does not permit determination of causal
associations. The survey questioned participants about
whether they had asked their partners if they had been
tested, but (1) did not follow up to ask whether partners had
responded to the question or what those test results were
and (2) whether discussions of serostatus happened before
or after initiation of the sexual partnership. These meth-
odological problems have been noted elsewhere [27]. We
therefore cannot ascertain the degree to which a recent
negative test is associated with protected sex with HIV-
positive partners who are aware of their infection. Detailed
data about the timing of disclosure relative to the onset of
sexual relations should be collected in future studies.
Further research is needed to understand the process by
which individuals ascertain their partners’ HIV serostatus
and to identify those factors which enter into condom use
decisions. Finally, the study from which the data for this
analysis were taken did not inquire whether HIV-diagnosed
participants had been declined by potential sexual partners
due to participants’ disclosure of HIV-positive status; while
taking such scenarios into account would not change the
proportion of partnerships in which condoms were used, it
would impact the proportion of unprotected partnerships
occurring post-disclosure.
Evidence from studies outside of Russia suggests that
sexual risk behaviors may contribute more than injection
risk behaviors to HIV transmission among IDUs when
injection risks are reduced through educational, behavioral,
or structural interventions [56, 57], but few interventions
speciﬁcally target the reduction of sexual risk among this
population [58]. Our experience working with this popu-
lation in St. Petersburg indicates that condoms are readily
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123available and inexpensive at most convenience stores,
pharmacies, and kiosks; they are also free at syringe
exchanges and outreach programs. There are few published
reports of condom use rates among IDUs or even within the
general population of Russia, and even less is known about
these rates among partner types (e.g., new, main, casual
partners). However, there is some evidence that condom
use rates are generally low, with 45% of injectors in one
study reporting no condom use in the previous 6 months
[59], another study noting consistent condom use for only
44% of a sample of Moscow youths [60], and 19–25% of
respondents in a representative probability sample of
Russian households reporting condom use at their last
sexual encounter [61]. Elsewhere in the world the rates of
unprotected sex for IDUs ranged from 28 to 77% [62–68].
Our ﬁndings suggest the need for interventions targeting
increased condom use among Russian IDUs and that HIV
testing—and provision of test results—should be encour-
aged among all members of social networks in which HIV
is prevalent. In our analysis fewer than half the participants
were aware of their infection, but when aware, condom use
was signiﬁcantly more likely to occur with partners per-
ceived to be seronegative. These ﬁndings, compounded
with the negative association between condom use and
disclosure, suggest that public health beneﬁt (in terms of
decreasing sexual exposure to HIV by uninfected partners)
may accrue from the scaling up HIV testing services and
interventions that increase the likelihood of individuals
receiving their test results.
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